Kintara Therapeutics, Inc. - KTRA STOCK NEWS

The Global Coalition for Adaptive Research has activated Kazia's paxalisib and Kintara's VAL-083 in the GBM AGILE trial, aimed at treating glioblastoma, the most aggressive brain cancer. This adaptive platform trial, which began screening patients in 2019, allows simultaneous evaluation of multiple therapies. Paxalisib targets the PI3K/AKT/mTOR pathway, while VAL-083 addresses MGMT resistance. The trial is set to expand to over 30 U.S. sites, enhancing access to cutting-edge therapies for GBM patients.

Kintara Therapeutics (Nasdaq: KTRA) announced that President and CEO Saiid Zarrabian will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available on-demand from January 11 at 6:00 A.M. ET. Kintara is developing innovative cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. Both programs are in late-stage development with promising clinical results, particularly REM-001, which has shown an 80% complete response rate in prior trials.

Kintara Therapeutics (Nasdaq: KTRA) announced its presentation at the 2nd Annual Glioblastoma Drug Development Virtual Summit on December 10, 2020, at 11:45 A.M. EST. Dr. John de Groot and Dr. James Perry will discuss VAL-083, a first-in-class bifunctional alkylating agent showing promise against both MGMT unmethylated and methylated glioblastoma. Kintara is committed to developing novel cancer therapies, including VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer, addressing significant unmet medical needs.

Kintara Therapeutics (KTRA) announced positive interim data from two Phase 2 trials of VAL-083 for glioblastoma multiforme (GBM). The studies revealed a median progression-free survival (PFS) of 10.0 months for newly-diagnosed patients receiving VAL-083 as adjuvant therapy, outpacing historical controls. In recurrent GBM patients, the median overall survival (mOS) reached 8.5 months, exceeding lomustine benchmarks. The data will be presented at the Society for Neuro-Oncology's Annual Meeting. Challenges include myelosuppression as a common adverse event, highlighted in the trials.

Kintara Therapeutics (Nasdaq: KTRA) reported financial results for Q1 FY2021, ending September 30, 2020. The company achieved a major milestone by acquiring Adgero, enhancing its pipeline focused on solid tumor cancer therapies. They completed a $25 million private placement. Cash and equivalents stood at $22.6 million, expected to fund operations into Q4 2021. Kintara incurred a net loss of approximately $19.5 million ($1.33 per share), significantly up from $1.6 million ($0.21 per share) a year prior, largely due to $16 million in non-cash acquisition expenses.

Kintara Therapeutics (KTRA) announced a significant partnership with the Global Coalition for Adaptive Research (GCAR) for its VAL-083 drug's inclusion in the GBM AGILE Study, aimed at accelerating the identification of effective glioblastoma therapies. This collaboration enhances operational efficiency by managing all study aspects, increasing trial sites in the U.S. from 24 to 31 with potential expansion. Kintara will supply VAL-083 and funding for the study, expected to expedite FDA approval processes.

Kintara Therapeutics (KTRA) reported its financial results for the year ended June 30, 2020, highlighting a net loss of $9.1 million or $0.87 per share, up from a loss of $8.0 million or $3.16 per share in the prior year. Key corporate events include a $25 million private placement and the acquisition of Adgero Biopharmaceuticals, enhancing its oncology pipeline. The company has cash reserves of approximately $2.4 million, supplemented by the recent funding, which is expected to support operations into Q4 2021. Kintara is advancing clinical studies for VAL-083 and REM-001.

Kintara Therapeutics (Nasdaq: KTRA) has successfully closed a private placement of Series C Convertible Preferred Stock, raising approximately $25 million. The funds will support its strategic aim of developing therapies for rare cancer indications, specifically to finance the registration study for VAL-083 in glioblastoma multiforme and a confirmatory study for REM-001 in cutaneous metastatic breast cancer. The company anticipates that this capital will enable the achievement of significant clinical milestones over the next 12-24 months.

Kintara Therapeutics (Nasdaq: KTRA) will have its CEO, Saiid Zarrabian, present at the LD Micro 500 virtual conference on September 3, 2020, at 4:00 PM ET. The presentation will be followed by a live Q&A session with attendees. Zarrabian is also available for one-on-one meetings from September 1-4, 2020. Kintara focuses on developing cancer therapies, notably VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer, both of which are in late-stage clinical trials aimed at addressing significant unmet medical needs.